MR Imaging in Spinocerebellar Ataxias: A Systematic Review

BACKGROUND AND PURPOSE: Polyglutamine expansion spinocerebellar ataxias are autosomal dominant slowly progressive neurodegenerative diseases with no current treatment. MR imaging is the best-studied surrogate biomarker candidate for polyglutamine expansion spinocerebellar ataxias, though with conflicting results. We aimed to review quantitative central nervous system MR imaging technique findings in patients with polyglutamine expansion spinocerebellar ataxias and correlations with well-established clinical and molecular disease markers. MATERIALS AND METHODS: We searched MEDLINE, LILACS, and Cochrane data bases of clinical trials between January 1995 and January 2016, for quantitative MR imaging volumetric approaches, MR spectroscopy, diffusion tensor imaging, or other quantitative techniques, comparing patients with polyglutamine expansion spinocerebellar ataxias (SCAs) with controls. Pertinent details for each study regarding participants, imaging methods, and results were extracted. RESULTS: After reviewing the 706 results, 18 studies were suitable for inclusion: 2 studies in SCA1, 1 in SCA2, 15 in SCA3, 1 in SCA7, 1 in SCA1 and SCA6 presymptomatic carriers, and none in SCA17 and dentatorubropallidoluysian atrophy. Cerebellar hemispheres and vermis, whole brain stem, midbrain, pons, medulla oblongata, cervical spine, striatum, and thalamus presented significant atrophy in SCA3. The caudate, putamen and whole brain stem presented similar sensitivity to change compared with ataxia scales after 2 years of follow-up in a single prospective study in SCA3. MR spectroscopy and DTI showed abnormalities only in cross-sectional studies in SCA3. Results from single studies in other polyglutamine expansion spinocerebellar ataxias should be replicated in different cohorts. CONCLUSIONS: Additional cross-sectional and prospective volumetric analysis, MR spectroscopy, and DTI studies are necessary in polyglutamine expansion spinocerebellar ataxias. The properties of preclinical disease biomarkers (presymptomatic) of MR imaging should be targeted in future studies.

[1]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[2]  Douglas N. Greve,et al.  An Absolute Beginner's Guide to Surface- and Voxel-based Morphometric Analysis , 2011 .

[3]  F. Cendes,et al.  Cerebral cortex involvement in Machado−Joseph disease , 2015, European journal of neurology.

[4]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2009, Journal of clinical epidemiology.

[5]  R. Valabrègue,et al.  In vivo neurometabolic profiling in patients with spinocerebellar ataxia types 1, 2, 3, and 7 , 2015, Movement disorders : official journal of the Movement Disorder Society.

[6]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[7]  C. Kieling,et al.  Progression Rate of Neurological Deficits in a 10-Year Cohort of SCA3 Patients , 2010, The Cerebellum.

[8]  Raffaele Cacciaglia,et al.  Amygdalar and hippocampal volume: A comparison between manual segmentation, Freesurfer and VBM , 2015, Journal of Neuroscience Methods.

[9]  T. Vangberg,et al.  How Does the Accuracy of Intracranial Volume Measurements Affect Normalized Brain Volumes? Sample Size Estimates Based on 966 Subjects from the HUNT MRI Cohort , 2015, American Journal of Neuroradiology.

[10]  Raymond W Lam,et al.  Using Metaanalysis to Evaluate Evidence: Practical Tips and Traps , 2005, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[11]  D. Salat,et al.  PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease , 2014, Neurology.

[12]  F. Cendes,et al.  Axonal Dysfunction in the Deep White Matter in Machado‐Joseph Disease , 2009, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[13]  D. Timmann,et al.  The natural history of spinocerebellar ataxia type 1, 2, 3, and 6 , 2011, Neurology.

[14]  Po-Shan Wang,et al.  Association between Proton Magnetic Resonance Spectroscopy Measurements and CAG Repeat Number in Patients with Spinocerebellar Ataxias 2, 3, or 6 , 2012, PloS one.

[15]  Till-Karsten Hauser,et al.  Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6. , 2013, Brain : a journal of neurology.

[16]  Í. Lopes-Cendes,et al.  Nonmotor and extracerebellar features in Machado‐Joseph disease: A review , 2013, Movement disorders : official journal of the Movement Disorder Society.

[17]  C. Yasuda,et al.  A multimodal evaluation of microstructural white matter damage in spinocerebellar ataxia type 3 , 2013, Movement disorders : official journal of the Movement Disorder Society.

[18]  Paula Coutinho,et al.  The Global Epidemiology of Hereditary Ataxia and Spastic Paraplegia: A Systematic Review of Prevalence Studies , 2014, Neuroepidemiology.

[19]  Lippincott Williams Wilkins,et al.  Scale for the assessment and rating of ataxia: Development of a new clinical scale , 2006, Neurology.

[20]  Georg Auburger,et al.  Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7 , 2013, Progress in Neurobiology.

[21]  Po-Shan Wang,et al.  Change in the Cortical Complexity of Spinocerebellar Ataxia Type 3 Appears Earlier than Clinical Symptoms , 2015, PloS one.

[22]  Í. Lopes-Cendes,et al.  Spinal Cord Damage in Machado-Joseph Disease , 2014, The Cerebellum.

[23]  Mario Mascalchi,et al.  Brain structural damage in spinocerebellar ataxia type 2. A voxel‐based morphometry study , 2008, Movement disorders : official journal of the Movement Disorder Society.

[24]  W. Liao,et al.  Spin labeling artery method perfusion MRI study of SPG4 and SCA3/MJD. , 2014, Magnetic resonance imaging.

[25]  T. Gheno,et al.  Planning future clinical trials in Machado Joseph disease: Lessons from a phase 2 trial , 2015, Journal of the Neurological Sciences.

[26]  T. Bird.  Hereditary Ataxia Overview , 2016 .

[27]  Peter Bauer,et al.  Visualization, quantification and correlation of brain atrophy with clinical symptoms in spinocerebellar ataxia types 1, 3 and 6 , 2010, NeuroImage.

[28]  D. Souza,et al.  A randomized, phase 2 clinical trial of lithium carbonate in Machado‐Joseph disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[29]  Nikolaus Weiskopf,et al.  A comparison between voxel-based cortical thickness and voxel-based morphometry in normal aging , 2009, NeuroImage.

[30]  Lars Johansson,et al.  Intracranial volume estimated with commonly used methods could introduce bias in studies including brain volume measurements , 2013, NeuroImage.

[31]  Alexandra Durr,et al.  Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data , 2013, The Lancet Neurology.

[32]  Alan C. Evans,et al.  Three-Dimensional MRI Atlas of the Human Cerebellum in Proportional Stereotaxic Space , 1999, NeuroImage.

[33]  R. Fimmers,et al.  Responsiveness of different rating instruments in spinocerebellar ataxia patients , 2010, Neurology.

[34]  Anders M. Dale,et al.  An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest , 2006, NeuroImage.

[35]  R. Díaz,et al.  Specific cerebellar and cortical degeneration correlates with ataxia severity in spinocerebellar ataxia type 7 , 2015, Brain Imaging and Behavior.

[36]  Po-Shan Wang,et al.  Differences between Spinocerebellar Ataxias and Multiple System Atrophy-Cerebellar Type on Proton Magnetic Resonance Spectroscopy , 2012, PloS one.

[37]  Pilar Latorre,et al.  Ataxia Rating Scales—Psychometric Profiles, Natural History and Their Application in Clinical Trials , 2011, The Cerebellum.

[38]  Alexandra Durr,et al.  Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond , 2010, The Lancet Neurology.

[39]  C. Yasuda,et al.  Thalamic Volume and Dystonia in Machado–Joseph Disease , 2011, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[40]  C. Yasuda,et al.  Widespread neuronal damage and cognitive dysfunction in spinocerebellar ataxia type 3 , 2013, Journal of Neurology.

[41]  L. Jardim,et al.  Machado Joseph disease: clinical and genetic aspects, and current treatment , 2015 .

[42]  C. Kieling,et al.  A neurological examination score for the assessment of spinocerebellar ataxia 3 (SCA3) , 2008, European journal of neurology.

[43]  C. Yasuda,et al.  Neocortical Atrophy in Machado‐Joseph Disease: A Longitudinal Neuroimaging Study , 2012, Journal of neuroimaging : official journal of the American Society of Neuroimaging.